RPL38

Across TCGA pan-cancer cohorts, RPL38 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPL38 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL38 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL38 expression acts as an unfavorable survival marker.

STAD and CHOL are the cancer types where RPL38 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPL38–STAD (OS)

Open the STAD breakdown →